SI
Sentrimed, Inc.
SEC filingBiotechnology · Mullica Hill, NJ
Amount raised$250Ksold at filing
Total offering$1M$750K still open
Investors in the raise1count reported to the SEC
FiledMay 13, 2026first sale May 8, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Arye Rhodehamel RosenExecutive Officer
Jack GoldbergExecutive Officer, Director
Mari Rhodehamel YinExecutive Officer, Director
Gary Rhodehamel GoldbergExecutive Officer
William RagatzExecutive Officer, Director
Christopher Rhodehamel LeonardExecutive Officer
Bradley GalerDirector
Tabbetha Rhodehamel DobbinsDirector
Executive officers, directors and promoters as listed on the Form D.